Free Trial
OTCMKTS:MRMD

MariMed Q2 2025 Earnings Report

MariMed logo
$0.10 +0.00 (+0.39%)
As of 07/11/2025 03:59 PM Eastern

MariMed EPS Results

Actual EPS
N/A
Consensus EPS
-$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

MariMed Revenue Results

Actual Revenue
N/A
Expected Revenue
$40.80 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

MariMed Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

MariMed Earnings Headlines

MariMed Announces Second Quarter 2025 Earnings Date
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More MariMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MariMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MariMed and other key companies, straight to your email.

About MariMed

MariMed (OTCMKTS:MRMD) (OTCMKTS: MRMD) is a diversified cannabis and wellness company that develops, manages and operates state-licensed facilities across the United States. Founded in 2013 and headquartered in Boston, MariMed focuses on delivering regulated medical and adult-use cannabis products, with a complementary advisory business that assists municipalities, real estate owners and other operators through the licensing and compliance process. The company’s vertically integrated model includes cultivation, extraction, manufacturing, and retail, allowing end-to-end oversight of product quality, safety and consistency.

Through its wholly owned subsidiaries and partnerships, MariMed holds licenses in key markets including Massachusetts, Maryland, Illinois, Maine, Rhode Island and Pennsylvania. Its cultivation sites utilize proprietary environmental controls and data-driven analytics to optimize plant health and cannabinoid profiles. The company’s manufacturing facilities employ state-of-the-art extraction and infusion technology, enabling scalable production of oils, distillates and concentrates. MariMed also operates multiple dispensaries under its flagship brands, ensuring that patients and consumers have access to a curated selection of products.

MariMed’s branded portfolio spans a wide range of delivery formats, from vape cartridges, tinctures and transdermal gels to edible gummies and chocolate bars. Signature labels include Nature’s Heritage™, Bliss by MariMed™ and Kalm Fusion™, each formulated to address specific wellness needs such as pain relief, stress management and sleep support. Products undergo rigorous testing by independent laboratories to verify potency, purity and compliance with state regulations, reinforcing the company’s commitment to responsible, patient-centered care.

Under the leadership of Founder and CEO Frank L. Connolly, MariMed has grown into one of the industry’s pioneering multi-state operators. Connolly and his executive team bring experience in pharmaceuticals, food and beverage manufacturing, and regulatory policy, guiding the company through evolving compliance landscapes. In parallel to its core cultivation and retail activities, MariMed Advisors offers consulting services in licensing strategy, facility design and operational best practices, helping new and established businesses navigate complex regulatory frameworks.

View MariMed Profile

More Earnings Resources from MarketBeat